Small Cap Soars On FDA Submission Plans

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, December 10, 2024

A healthcare company based out of North Carolina is turning heads so far during Tuesday’s session after the company announced that it plans to submit its Dordaviprone for accelerated approval to the Food and Drug Administration (FDA) before the end of the year.

Traders were quick to buy up shares of Chimerix Inc. (Nasdaq:CMRX), which caused this small cap to open the session up at $2.18/share (+152.02%). This massive move compounds the gains this stock experienced over the last few months.

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.